Acadia Pharmaceuticals Inc. (ACAD)

[IanFromSI]

I should live so long

[harry crumb]

Oh it’l happen, enough said

[IanFromSI]

Harry, I haven’t seen any buyout rumours for Acadia since March 2015. What are you talking about or hoping for?

Please provide a link.

[harry crumb]

27k shares waiting on the buyout news! Happy early retirement all over again
$$$$$$

[harry crumb]

Boom

[harry crumb]

Keeps going up here

[Monksdream]

ACAD new 52 week high

[harry crumb]

Boom

[IanFromSI]

Shares of Acadia climbed 17% in after-hours trading Thursday.

Price: 30.25, Change: +4.45, Percent Change: +17.25



ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours
2023-07-13 05:26:11 PM ET (MT Newswires)


05:26 PM EDT, 07/13/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) said Thursday it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug.

The agreement also gives Acadia global rights to Neuren's NNZ-2591 in Rett syndrome and Fragile X syndrome.

Under the agreement, Neuren will receive an upfront payment of $100 million and may receive potential downstream milestone and royalty payments earned separately for trofinetide and NNZ-2591.

Outside of North America, Neuren may receive additional payments for trofinetide upon the achievement of certain revenue milestones and it will also get tiered royalties from the mid-teens to low-twenties percent of trofinetide sales.

Potential future payments to Neuren related to NNZ-2591 in Rett syndrome and Fragile X syndrome are equal to the payments for trofinetide in each of North America and outside North America, Acadia said.

Acadia said it plans to submit a new drug submission for trofinetide in Canada in the next 18 months. It will announce plans for Europe, Asia and other regions at a later date.

Shares of Acadia climbed 17% in after-hours trading Thursday.

Price: 30.25, Change: +4.45, Percent Change: +17.25

[harry crumb]

Beautiful day $$$$

[Doktornolittle]

Is Martin Shkreli in charge of Acadia, or some other cold psycho-bstrd? Shkreli was released to a half way house in May of last year.

https://www.cnbc.com/2022/05/18/martin-shkreli-released-from-federal-prison-into-halfway-house-.html#:~:text=Shkreli%20was%20arrested%20in%20late,that%20he%20had%20covered%20up.

https://www.marketwatch.com/story/acadias-rare-disease-drug-to-cost-575-000-to-595-000-5e883843

https://news.sky.com/story/martin-shkreli-man-who-made-huge-profits-by-inflating-price-of-life-saving-drug-ordered-to-return-47m-12516161#:~:text=Data%20%26%20Forensics-,Martin%20Shkreli%3A%20Man%20who%20made%20huge%20profits%20by%20inflating%20price,rights%20to%20it%20in%202015.

[harry crumb]

30’s coming folks, patience

[MiamiGent]

ACAD hopefully Opening will give a boost but I just got out with a meager profit, not appreciating P-M action. I'm playing for a batting average this year and keep my distance from red. GL!

[harry crumb]

If the price is right, yes

[my74nova]

Or dumb for not selling when it was in the upper $50's years ago. ;)

[MiamiGent]

Phew, $2.1>. Nice!
You are patient..

[my74nova]

Mine are at $2.18.....been holding for a looong time. Hope we can get back into the upper $50's and maybe beyond.

Do you think anyone would want to do a buyout?

[MiamiGent]

ACAD...... APPROVED!

[harry crumb]

Strong ticker

[harry crumb]

Still hold shares at 5.00 here

[harry crumb]

Nice day for acad holders??

[IanFromSI]

$ACAD is covered by 10 analysts:

Sell zero
Neutral seven
Buy three

RBC Boosts Price Target on ACADIA Pharmaceuticals to $27 From $19, Maintains Outperform Rating
2023-02-28 08:14:38 AM ET (MT Newswires)


08:14 AM EST, 02/28/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $10 to $28.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

[harry crumb]

Throughout market turmoil thanks to biden an his brainless entourage acad holding up well in portfolio’s $$$$

[harry crumb]

1 an 3 month chart are winners for those who added! $$$$

[harry crumb]

Lmao shorty, the BB’s are far more advanced than you, i kno them well, GL an in the trading world there is a word spelled c o v e r, If i were you i would look up what it means. Enough said, happy trading folks, patience…. $$$$

[gi197845]

An ironic twist of fate.
The law of unintended consequences.
Most of you are overly invested in Acadia pharma.
Most of you are deep underwater with your investment.
Most of you have averaged down and even taken out a 2nd mortgage to do so.
Most of you are hoping that Trofinetide will be FDA approved for RETT syndrome on March 12th, 2023.
Most of you think Acadia's share price will rise upon FDA approval.
Most of you are just hoping to break even to bail out of this Titanic boat anchor.
Most of you don't realize that the stock price will dive upon Trofinetide approval.
It costs more to manufacture and sell Trofinetide, than full sales could ever pay for let alone make a profit.
The same is true of Nuplazid, it costs more to manufacture and sell, than any meager "profits" can bring in.
The Baker Brothers only own Acadia pharma stock, as a tax write-off...
Every hedge fund, needs one bad apple in the bunch, just to offset taxes on the other, profitable holdings.
Criss-Cross, you bet the wrong dog!

[gi197845]

The volume today has been only the selling of shares, back into the public float/pool, no one is buying shares, hence the downward pressure on the stock price. It's simply not true that for every seller, there is a buyer, there are many shares still in the public float that Acadia owns, to sell into the market, for their own financial gain, when and if those shares are purchased. When a person buys a stock out of the public float pool, that money goes directly into Acadia's pockets...

[LasNubes]

Pretty standard stuff.
Most Pharma companies have legal issues like this.

None of this will move the needle in either direction IMHO

[gi197845]

OK, that's good but what about this?
https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/
2 people died because Acadia illegally hired a convicted felon as a pharma sales, rep that sold them fentanyl. Unlimited damages and liabilities. Why would Acadia hire a felon? Why does Stephen Davis have his shirt unbuttoned down so far during conference calls?

Uh Oh! what about this lawsuit??? Hmmm...????

NEW ORLEANS, Nov. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).

On July 20, 2020, the Company announced that the FDA had accepted for filing its supplemental new drug application ("sNDA") for its drug candidate, pimavanserin, for the treatment of dementia-related psychosis ("DRP"). Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug's efficacy. Then, on April 5, 2021, the Company disclosed that the FDA had rejected the sNDA, citing a lack of statistical significance regarding some of the subgroups of dementia and inadequate numbers of patients with some less common dementia subtypes.

[LasNubes]

ACAD is the plaintiff and filed suit due to patent infringement claims.

This is pretty standard stuff and actually good for ACAD that their patent attorneys are going after folks trying to jump their patents.

[gi197845]

Wow, yet another lawsuit!

https://casetext.com/case/acadia-pharm-v-aurobindo-pharma

[gi197845]

Uh oh, Acadia going out of business due to 2 wrongful death lawsuits, with unlimited damages.

https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/

[harry crumb]

Good pop today

[harry crumb]

Things like that happen with bio’s, it’’s still a promising company to invest in, theres other drug science capable of moving forward just like any other. those who followed us from the beginning of acad, at 2-5$ a share made a ton of wealth over the years whether they flipped in or out at variable times was their choice, its called trading, making wealth. To invest 25k at 3$ pps and to sell at 50 pps is a very large gain of wealth my friend. Those who didn’t sell well don’t blame acad for that. You think the BB’s invested not to sell? Ah, no they sure didn’t. We hold a chunk of acad yet but that is all free shares, no matter what price it goes to. As for other stocks you mentioned, it’s the same, wealth made an just sitting on free shares, who really cares what happens once your initial investment is paid for in gains. GL to you an never be greedy, take profits as u wish

[gi197845]

What about the latest shelf offering and the lowered guidance? Do you enjoy it?

[harry crumb]

Ah listen pal, before u make a comment you should know what exactly your commenting on! Acad has made investors millions of dollars since the beginning stages of its first trial an first nda! I guess you do not know this, over the years investing in this company has been nothing but positive an for someone like you to comment on an issue you have no clue about is absurd! Get lost an go crawl under a rock

[gi197845]

Big mistake listening to Harry Crumb! Keep in mind that he invested in a used car salesman owned scam with with water less tooth brushes and paper less toilet paper.

[gi197845]

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID(R) (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

The CRL indicated that the FDA has completed review of the application, determining that it could not approve the sNDA in its present form, and recommended that Acadia conduct an additional trial in ADP. While the FDA stated that Study 019 demonstrated a statistically significant treatment effect on its primary endpoint, they concluded that there are limitations in the interpretability of the 019 results. The FDA also stated that the positive treatment effect of pimavanserin on dementia-related psychosis in Study 045 (HARMONY) appeared to be driven by the robustly positive results in the Parkinson's disease dementia subgroup, a condition they stated is subsumed within the currently approved NUPLAZID Parkinson's disease psychosis (PDP) indication. Up to 50 percent of PDP patients have dementia.(1)

"We are disappointed with this outcome. The treatment of Alzheimer's disease psychosis continues to be an area of high unmet need, for which there is no approved therapy," said Steve Davis, Chief Executive Officer. "We want to express our gratitude to all of the patients, their families and investigators who have participated in our clinical trials."

NUPLAZID was approved in the U.S. in 2016 and is the first and only treatment for hallucinations and delusions associated with PDP.

[gi197845]

Smell my shorts, shortie! In your face!

[gi197845]

State of New Jersey Common Pension Fund D trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) by 34.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,642 shares of the biopharmaceutical company’s stock after selling 50,023 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in ACADIA Pharmaceuticals were worth $2,341,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Lazard Asset Management LLC grew its position in shares of ACADIA Pharmaceuticals by 19.4% in the 4th quarter. Lazard Asset Management LLC now owns 3,115 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 506 shares during the last quarter. Personal CFO Solutions LLC grew its position in shares of ACADIA Pharmaceuticals by 6.7% in the 1st quarter. Personal CFO Solutions LLC now owns 15,846 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 1,000 shares during the last quarter. Kalos Management Inc. grew its position in shares of ACADIA Pharmaceuticals by 6.0% in the 4th quarter. Kalos Management Inc. now owns 19,689 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 1,114 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,927 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 1,334 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of ACADIA Pharmaceuticals by 2.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 68,700 shares of the biopharmaceutical company’s stock valued at $1,637,000 after buying an additional 1,800 shares during the last quarter. 91.74% of the stock is owned by hedge funds and other institutional investors.

[gi197845]

I figured it out. The only reason why the successful baker brothers have shares of Acadia is for tax right off purposes, to offset the huge profits from their other well managed pharmas.

[gi197845]

Hey foo, I hope your shorting this!

[gi197845]

I figured it out. The only reason why the successful baker brothers have shares of Acadia is for tax right off purposes, to offset the huge profits from their other well managed pharmas.

[gi197845]

I agree, Trofinetide is a great, big and expensive joke as compared to A2-73 and thus far, I have lost 43% of my ACAD-EEEEEGAAAAADS! investment, so expecting to lose the other 57% on Thursday, August 4th 2022.

[IanFromSI]

with an opened-shirt and flabby belly hanging out during the conference call meetings.

Why do you post such superfluous BS?

Do you think that doing so on an unread thread will drive the price lower so you can buy more shares cheaper?

Are you just a disgruntled former or current employee?

Did you fall in love with him and get flat out rejected? Did he call you fat, slovenly or both?

Why do you waste your time and every one else's here?

Just curious...

[IanFromSI]

And here's one from only 2 days ago...


ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from SVB Securities
July 11 2022 - 08:39AM

In a report released today, Marc Goodman from SVB Securities maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $27.00. The company's shares closed last Friday at $15.74.

ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $22.64, representing a 45.7% upside.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-rating-from-svb-securities?utm_source=advfn.com&utm_medium=referral

[IanFromSI]

- If you really need to go all the way back to June 21st, here's another analyst on that same day.


ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from JMP Securities
June 21 2022 - 08:26AM
TipRanks

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed last Thursday at $19.51.

Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $27.17, a 39.4% upside from current levels.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-rating-from-jmp-securities?utm_source=advfn.com&utm_medium=referral

[gi197845]

Steve Davis knew that submitting the sNDA a 2nd time for ADP, without any new information, without any additional data, without any changes and without explaining anything positive to the Adcom, that it would be rejected again and that it would crash the stock price, so that's why he sold so much stock recently. Perhaps after 8/4/22, he will buy shares back at $7 ? Only to fumble more and more later, with an opened-shirt and flabby belly hanging out during the conference call meetings.

[gi197845]

Jefferies Financial Group cut shares of ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and decreased their price objective for the company from $25.00 to $10.00 in a report on Tuesday, June 21st.

[gi197845]

How much have you lost on Acadia? I mean thus far? How much more will you lose after the 8/4/22 PDFU date?